Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PHCC Priority Healthcare -- Ignore unavailable to you. Want to Upgrade?

To: Angler who wrote (7)	12/17/2000 9:06:55 AM
From: blebovits	Read Replies (1) \| Respond to of 103

<To what do you attribute this sudden rise in stock price?> Coverage initiated on Priority Hlthcare by Thomas Weisel!!! <Will you buy more at this price?> no !

To: Angler who wrote (7)	12/24/2000 12:20:47 AM
From: blebovits	Respond to of 103

Lehman analyst Larry Marsh raised his price target to $44 from $37.50 RESEARCH ALERT - Priority Healthcare price target raised NEW YORK, Dec 19 (Reuters) - Lehman Brothers on Tuesday said it raised Priority Healthcare Corp.'s <PHCC.O> 12-month stock price target after the healthcare products distributor unveiled plans to purchase Freedom Drug. The purchase of specialty pharmacy Freedom Drug, announced Monday, is expected to close in 2001 and boost earnings immediately. Lehman analyst Larry Marsh raised his price target to $44 from $37.50 in response, he said. Marsh forecast that the deal could boost Priority Healthcare earnings per share by 3 cents to 6 cents a year, with most gains occurring in 2001. "We see this addition to be a very nice broadening of (Priority)," Marsh wrote in a report issued Tuesday. Shares closed Monday at $33-1/2 on the Nasdaq, off a 52-week high of $40-1/4, but above a low of $11-5/8.